Chai Discovery
CA - San FranciscoBiotechnology
Focus: Chai Discovery is an AI-driven antibody discovery platform backed by OpenAI, recently valued at $1B and focused on accelerating drug discovery in neurology and ophthalmology. The company represents a new paradigm in computational drug discovery, leveraging machine learning to disrupt traditional antibody development workflows.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
14
Should You Work at Chai Discovery?
AI assessmentHigh-upside, high-risk opportunity best suited for technologists and scientists betting on AI-first drug discovery paradigm shift rather than those seeking clinical validation or financial stability.
Why Work Here
- Join a $1B-valued AI biotech at the inflection point of computational drug discovery, with OpenAI backing and mainstream pharma validation
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Chai Discovery
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.